CTLA4 and rheumatoid arthritis: Abatacept (CTLA4-Ig) is a bDMARD approved for use in patients with highly active and progressive RA who were not previously treated with MTX, or for treatment of moderate-to-severe active RA in patients with an inadequate response to previous therapy with at least one cDMARD [195].